GRCE - רווח תפעולי לפני ניכוי פחת Grace Therapeutics, Inc.

Sales expansion in the US and Europe reduces the risks of regional dependency for Grace Therapeutics, Inc. (GRCE), and the EBITDA level reflects the dynamics of this process, where 0.00 shows the current value of the metric. Efficiency is increasing due to unique drug delivery systems, while stable demand for biotechnology protects the business from global recessions and macroeconomic volatility.
Grace Therapeutics (GRCE) - פילוחי מדדים ודוחות פיננסיים

Grace Therapeutics, Inc. (GRCE) focuses on creating innovative molecule delivery systems across the blood-brain barrier for the therapy of rare neurological pathologies. This metric measures net cash flow from operating activities before depreciation and taxes, reflecting the efficiency of R&D processes; meanwhile, the narrow sideways corridor of absolute operating cash results signals a consolidation of demand ahead of a new fundamental impulse.